Skip to main content

Table 3 Patient sociodemographic and clinical characteristics

From: Physician-perceived utility of the EORTC QLQ-GINET21 questionnaire in the treatment of patients with gastrointestinal neuroendocrine tumours: a multicentre, cross-sectional survey (QUALINETS)

Characteristic Patientsa
Age, years, mean (SD) 61.9 (13.1)
Sex , n (%)  
Male 111 (55.8%)
Female 88 (44.2%)
Marital status (n = 186), n (%)  
Married/co-habitation 135 (72.6%)
Single 20 (10.8%)
Widowed 18 (9.7%)
Separated/divorced 13 (7.0%)
Educational leve [(n = 179), n (%)]  
No formal education 18 (10.1%)
Primary education 68 (38.0%)
Secondary education 52 (29.1%)
University studies/postgraduate studies 41 (22.9%)
Time elapsed in years since diagnosis of GI-NET , mean (SD) 2.87 (3.6)
Time elapsed (years) since the 1 st intervention , mean (SD) 2.73 (3.6)
Time elapsed (months) between diagnosis and 1 st intervention , mean (SD) 1.7 (5.9)
Pharmacological treatment , n (%)  
No current pharmacological treatment 67 (33.7%)
Somatostatin analogues 113 (56.8%)
Chemotherapy 21 (10.6%)
Interferon 2 (1.0%)
Targeted therapy 21 (10.6%)
Other 5 (2.5%)
Presence of symptoms , n (%)  
No 104 (52.3%)
Yes 95 (47.7%)
Clinical status according to treating physicianb, n (%)  
Stable 151 (75.9%)
Worsening 20 (10.1%)
Improving 28 (14.1%)
ECOG scores, n (%)  
ECOG 0 100 (50.3%)
ECOG 1 81 (40.7%)
ECOG 2 16 (8.0%)
ECOG 3 2 (1.0%)
Presence of concomitant illness, n (%) 75 (37.7%)
No  
Yes 124 (62.3%)
Clinical assessment of patient’s health, n (%)  
Good 169 (84.9%)
Neither good nor poor 9 (4.5%)
Poor 21 (10.6%)
  1. aAll data, except where indicated otherwise, are based on the full sample (n = 199). In all cases, the percentages are calculated based on the available data
  2. bBased on general clinical assessment and, when available, data from biochemical, immunohistochemical, and/or imaging studies
  3. ECOG, European Cooperative Oncology Group; GI-NET, gastrointestinal neuroendocrine tumour; SD, standard deviation